Concert Pharmaceuticals Selected by AlwaysOn as an OnDC Top 100 Winner

Concert Pharmaceuticals, Inc. is pleased to announce that it has been chosen by AlwaysOn as one of the OnDC Top 100 Winners. Inclusion in the OnDC 100 signifies major developments in the creation of new business opportunities that contribute to the renewed and continued prosperity of our country. Concert was specially selected by the AlwaysOn editorial team and industry experts based on a set of five criteria: innovation, market potential, commercialization, stakeholder value, and media buzz.

“It’s no secret that technology and innovation are vital to bringing our country out of economic recession and transforming important sectors like energy and healthcare,” said Tony Perkins, founder and CEO of AlwaysOn. “We congratulate the OnDC 100 for their success in introducing new tools, services, and systems to address the nation’s top priorities.”

“We are proud of what we’ve accomplished at Concert in a short period of time,” said Roger Tung, Ph.D., President and Chief Executive Officer. “We are pleased to receive this award, which recognizes innovation and contribution across the areas of greentech, on-demand computing and IT security, education, and the life sciences. This is a further testament to the potential of Concert’s rapid, reduce-risk approach to drug development, which we believe will allow us to bring many important new medicines to patients.”

The OnDC 100 winners were selected from among hundreds of other technology companies nominated by investors, bankers, journalists and industry insiders. The AlwaysOn editorial team conducted a rigorous three-month selection process to finalize the 2009 list. Concert Pharmaceuticals and the OnDC Top 100 Companies will be honored at AlwaysOn’s OnDC event on October 19th-21st at the Four Seasons Hotel in Washington DC.

A full list of all the OnDC Top 100 Winners can be found on the AlwaysOn Web site at http://alwayson.goingon.com/permalink/post/33638

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel and differentiated small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. Its lead development candidate is the HIV protease inhibitor CTP-518. In 2009, Concert entered into a potential $1 billion collaboration with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.

About AlwaysOn

AlwaysOn ignited the open-media revolution in early 2003 by being the first media brand to launch a global blog network. In 2004, AlwaysOn continued to lead the media industry in innovation by introducing a social network where members can connect and engage. AlwaysOn is also revolutionizing the media business by applying its open-media principles to its executive event series (Summit at Stanford, OnMedia, OnHollywood, OnDC, GoingGreen East and West, Venture Summit East and West) and quarterly print “blogozine” by empowering its members to post and share their ideas and meet each other online. As our loyal readers know, AlwaysOn is committed to the free-market, merit-driven approach to reporting and event programming. No other media brand has dared to create such open interaction with its readers and event participants.

Justine E. Koenigsberg
 

Senior Director, Corporate Communications and Investor Relations
Concert Pharmaceuticals, Inc.
99 Hayden Avenue, Suite 500, Lexington, MA 02421
781.674.5284